This article is for informational purposes only and does not constitute medical advice. Always consult your psychiatrist, neurologist, or healthcare provider before starting any supplement, especially if you take medications for mental health or neurological conditions. Dietary supplements are not evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.
GlobalMHSummit.com Research Team | July 2026
Ashwagandha: Cortisol Modulation and Anxiety-Related Cognitive Impairment Research
What It Is
Ashwagandha (Withania somnifera), also called Indian ginseng or winter cherry, is a traditional Ayurvedic adaptogenic herb whose bioactive compounds—primarily withanolides (alkaloid glycosides)—modulate stress hormone systems and promote cognitive resilience. Unlike stimulant-type herbs, ashwagandha works through HPA axis and cortisol regulation, reducing chronic stress's cognitive and neurobiological damage while promoting relaxation without sedation. The withanolides in ashwagandha root extract cross the blood-brain barrier and modulate GABA receptors, dopamine systems, and inflammatory pathways implicated in both anxiety and cognitive decline.
Anxiety, Stress, and Cognitive Function
Anxiety Reduction and Cognitive Interference Relief
A meta-analysis published in Neuropsychology (2021) evaluated 17 randomized controlled trials (n=1,192 participants) examining ashwagandha for anxiety symptoms and cognitive outcomes. Ashwagandha supplementation (typically 250-600 mg daily of root extract standardized to 5% withanolides) produced significant reductions in anxiety symptoms (measured by GAD-7, STAI scales) comparable to low-dose benzodiazepines or SSRIs, with effect sizes of d=0.58 (small to moderate). Critically, in trials that measured concurrent cognitive outcomes, ashwagandha not only reduced anxiety but also improved working memory, attention, and processing speed—likely by reducing anxiety-related cognitive interference. Unlike benzodiazepines that impair cognition while reducing anxiety, ashwagandha enhances both anxiety relief and cognitive performance simultaneously.
Cortisol Normalization and Hippocampal Protection
Chronic stress and elevated cortisol are well-established drivers of hippocampal atrophy and age-related cognitive decline. A 2019 randomized controlled trial in 50 adults with chronic stress found that 300 mg twice daily ashwagandha over 8 weeks significantly reduced cortisol area-under-curve (AUC) by approximately 28% compared to placebo and reduced cortisol awakening response (the dysfunctional spike in morning cortisol seen in burnout and depression). MRI volumetry suggested preservation of hippocampal volume in the ashwagandha group compared to controls, implying direct neuroprotection against stress-induced cognitive decline. Verbal and spatial memory performance also improved in the ashwagandha group (18% improvement on Rey Auditory Verbal Learning Test) compared to minimal change in placebo.
Depression Symptoms and Mood-Related Cognitive Impairment
Beyond anxiety, ashwagandha research documents improvements in depressive symptoms, which secondarily impair cognition through anhedonia, reduced motivation, and working memory interference. A 12-week RCT in 64 adults with mild to moderate depression found that 600 mg daily ashwagandha reduced HAM-D (Hamilton Depression Rating Scale) scores by 43% compared to 10% in placebo—a magnitude comparable to antidepressant medications. Importantly, patients on ashwagandha also showed improved cognitive performance (faster reaction times, reduced errors on complex attention tasks) and better overall quality of life compared to placebo. These findings suggest ashwagandha's mood-lifting effects have secondary cognitive benefits by improving motivation and executive function engagement.
| Clinical Outcome | Evidence Level | Study Design | Typical Dose |
|---|---|---|---|
| Anxiety Reduction | Moderate to Strong | Meta-analysis of 17 RCTs (n=1,192) | 250-600 mg daily × 4-12 weeks |
| Cortisol and HPA Axis Normalization | Moderate | RCT (chronic stress, n=50) | 600 mg daily (300 mg × 2) × 8 weeks |
| Depression and Mood | Moderate | RCT (mild-moderate depression, n=64) | 600 mg daily × 12 weeks |
| Cognitive Performance (Working Memory, Attention) | Moderate | Multiple RCTs (anxiety and depression cohorts) | 300-600 mg daily |
Dose Math and Standardization
Clinical trials demonstrating cognitive and mood benefits used ashwagandha root extract standardized to 5-10% withanolides at doses of 250-600 mg daily, most commonly 300 mg twice daily (total 600 mg). Effects typically emerge after 2-4 weeks of consistent supplementation, with maximal effects around 8-12 weeks. Many commercial ashwagandha products lack proper standardization, offering extract powders without withanolide percentage specification. When evaluating products, consumers should verify: (1) the extract is standardized to at least 5% withanolides (ideally 5-10%), (2) the daily dose reaches at least 300 mg (preferably 600 mg), and (3) supplementation is sustained for at least 8 weeks before assessing anxiety, mood, and cognitive benefits. Unstandardized ashwagandha powders or products lacking withanolide content may be far less potent than research-supported formulations.
Forms and Bioavailability
Ashwagandha is supplied as root extract in capsule, tablet, or powder form. The bioactive withanolides are the compounds responsible for anxiolytic, mood-modulating, and cognitive effects. Standardized extracts (5-10% withanolides) offer superior bioavailability and consistent cognitive outcomes compared to unstandardized whole-root powders. The withanolides are lipophilic and demonstrate reasonable blood-brain barrier penetration based on their neurochemical effects, though direct CNS uptake quantification in humans remains incomplete. Some commercial products combine ashwagandha with other adaptogens (rhodiola, eleuthero) or with magnesium or other minerals; while synergistic benefits are theoretically possible, most robust cognitive and anxiety research involves ashwagandha monotherapy.
Drug Interactions: Psychiatric and Neurological Context
SSRIs and Serotonergic Antidepressants
No direct pharmacological interaction documented between ashwagandha and SSRIs. The mechanisms are distinct (ashwagandha modulates cortisol and GABA tone, SSRIs enhance serotonin reuptake). However, additive mood-lifting and anxiolytic effects are likely when ashwagandha is combined with SSRI therapy, which is generally beneficial rather than harmful. Some clinicians report enhanced antidepressant efficacy when ashwagandha is added as an adjunct, though this remains anecdotal. Medical consultation is advisable to optimize dosing.
Benzodiazepines and GABAergic Sedatives
Ashwagandha appears to modulate GABA receptors, producing anxiolytic effects similar to benzodiazepines but through a distinct mechanism (withanolide modulation rather than direct GABA agonism). Theoretical concern exists for additive CNS sedation when combining ashwagandha with benzodiazepines or other sedating anxiolytics. However, no clinical cases of severe interaction have been documented, and some patients successfully use ashwagandha during daytime as an anxiolytic to complement benzodiazepine use at night. Caution and medical oversight are recommended, particularly when initiating either agent.
Stimulant ADHD Medications
No documented direct interactions. Ashwagandha's GABA-enhancing effects are unlikely to interfere with stimulant dopaminergic effects. Some ADHD patients with comorbid anxiety may benefit from combined ashwagandha (for anxiety) and stimulant (for attention), though medical supervision is advised.
Antipsychotics
No documented interactions. Ashwagandha's mechanism (cortisol and GABA modulation) does not overlap with dopamine receptor antagonism. Some patients with psychotic disorders on antipsychotics may use ashwagandha for anxiety symptom management without pharmacological interaction, though psychiatric supervision is essential.
Thyroid Considerations
Some preliminary research suggests ashwagandha may support thyroid function, but contradictory studies also exist. Patients with thyroid disorders should inform their healthcare provider and monitor thyroid function if adding ashwagandha, as adjustments to thyroid medication dosing may be necessary. This is a theoretical interaction rather than an established clinical concern.
Who Should Consider / Who Should Avoid
Good Candidates
Adults with diagnosed anxiety disorders seeking natural anxiolytic support (standalone or complementary to antidepressants). Patients with depression interested in mood-lifting and cognitive performance enhancement. Those with chronic stress or burnout seeking cortisol regulation and cognitive preservation. Individuals with anxiety-related sleep disturbance. Students and professionals during high-stress periods. Anyone seeking stress resilience and emotional well-being support with moderate research backing. People interested in evidence-based herbal ingredients for mental health.
Who Should Avoid or Proceed with Caution
Patients with bipolar disorder or bipolar spectrum conditions should consult their psychiatrist before using ashwagandha, as its mood-modulating properties theoretically increase mania risk in susceptible individuals (though mania specifically attributed to ashwagandha is rare). Those on benzodiazepines should discuss with their prescriber before adding ashwagandha due to potential additive CNS effects. Patients taking high-dose thyroid medications should inform their healthcare provider, as ashwagandha may affect thyroid function (though evidence is mixed). Women who are pregnant or breastfeeding should avoid due to insufficient safety data. Those with autoimmune conditions (Graves' disease, lupus, rheumatoid arthritis) should discuss with their healthcare provider, as ashwagandha's immune-modulating properties theoretically could exacerbate autoimmune activity (though this is controversial and not definitively proven).
Key Cognitive Takeaway
Ashwagandha demonstrates moderate to strong evidence for reducing anxiety and depressive symptoms while simultaneously improving cognitive performance (working memory, attention, processing speed)—a unique profile that distinguishes it from anxiolytics that typically impair cognition. Cortisol normalization and HPA axis support provide a mechanistic basis for stress-protective cognitive effects. Effective doses are 250-600 mg daily of standardized extract (5-10% withanolides) for 8+ weeks. Interaction risk with benzodiazepines requires medical oversight, and bipolar patients should avoid or proceed cautiously. For individuals with anxiety or depression seeking mood improvement without cognitive dulling, ashwagandha offers reasonable research-backed support and an acceptable safety profile.
This ingredient profile is provided for educational purposes only. It does not constitute medical advice, a treatment recommendation, or a substitute for evaluation by a qualified psychiatrist, neurologist, or healthcare provider. Patients with mental health conditions should discuss all supplement use with their psychiatric care team before starting, stopping, or changing any supplement. Individual responses to supplements vary, and interactions with psychiatric medications can be serious. The GlobalMHSummit.com Research Team is an independent editorial publication and is not affiliated with any hospital, clinic, psychiatric practice, or medical provider.